XBiotech Pauses Rheumatology program
December 23, 2024 09:00 ET
|
XBiotech Inc.
AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the...
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
December 23, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing...
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
December 20, 2024 00:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize...
NTHU Researchers Unveil the Mystery of Cancer Cells' Sugar Addiction
December 19, 2024 10:00 ET
|
NATIONAL TSING HUA UNIVERSITY
NTHU researchers uncover how cancer cells’ sugar addiction fuels growth, paving the way for potential new cancer treatments.
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 19, 2024 06:38 ET
|
Ocugen
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
December 18, 2024 07:00 ET
|
MannKind
MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH
BHIANT Celebrates Milestones in Workforce Development and Industry Collaboration, Sets Vision for 2025
December 17, 2024 10:00 ET
|
BHIANT
DALLAS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) proudly announces significant progress in workforce development and industry...
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
December 17, 2024 06:00 ET
|
Kynexis
KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1...